FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| l | OMB APPRO | VAL | | | | | | |
|---|--------------------------|-----------|--|--|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | | | |
| l | Estimated average burden | | | | | | | |
| l | hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Grossman Adam S | | | | | 2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA] | | | | | | | 5. Relationship of Reporting Person(s) to (Check all applicable) | | | | | |
|---|---|--|---|--|---|--|---|--|--|--|--|---|--|--|--|--|--|
| | | | | _ | | | | | | | | X | | | | % Owner | |
| (Last) (First) (Middle) C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/16/2015 | | | | | | | X Officer (give title Other (specify below) President & CEO | | | | | |
| | | | - 4. 11 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | |
| Y NJ | . (| 07446 | | - | , | | | | | | Line) X | 9) | | | | | |
| (St | ate) (| Zip) | | | | | | | | | | | | | | | |
| | Tabl | le I - 1 | Non-Deriv | /ative | Seci | uritie | s Ac | quire | d, D | isposed o | f, or B | enefi | cially | Owne | ed | | |
| 1. Title of Security (Instr. 3) 2. Transa Date | | | 2. Transact Date | ion | 2A. Deemed Execution Date, | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) o | | d (A) or | 5. Amount of Securities Beneficially Owned Followin | | unt of ties cially Following | Form: Direct | Indirect | |
| | | | | | | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) | | | | , , |
| Stock, \$0.0 | 001 par value pe | er | 03/16/2 | 015 | | | | P | | 8,500 | A | \$8.03 | 323(1) | 618, | 957(2)(3) | I | Please see footnote ⁽⁴⁾ |
| Common Stock, \$0.0001 par value per share | | | 03/16/2 | 015 | | | | P | | 300 | A | \$7.97 | \$7.9766 ⁽⁵⁾ | | 619,257 ⁽²⁾⁽³⁾ | | |
| Common Stock, \$0.0001 par value per share | | | 03/16/2 | 015 |)15 | | | P | | 100 | A | \$7. | \$7.97 | | 619,357(2)(3) | | By Child |
| Common Stock, \$0.0001 par value per share | | | | 2015 | | | | P | | 100 | A | \$7. | \$7.97 | | 457(2)(3) | I | By Child |
| Stock, \$0.0 | 001 par value pe | er | 03/16/2 | 015 | | | | P | | 100 | A | \$7. | 7.99 619,557 ⁽²⁾⁽³⁾ | | | I | By Child |
| Common Stock, \$0.0001 par value per share | | 03/17/2 | 7/2015 | | | | P | | 5,500 | A | \$7.9782(6) | | 625,057 ⁽²⁾⁽⁷⁾ | | I | Please see footnote ⁽⁴⁾ | |
| | Та | able II | | | | | | | | | | | | wned | | | |
| 1. Title of Derivative Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Ye) | | Execu | Execution Date, if any | | ransaction Code (Instr. | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | ation E | Date | Amoun Securit Underly Derivat | t of ies /ing ive | Der Sed (Ins | erivative ecurity | derivative Securities Beneficially Owned Following Reported | Owners Form: Direct (I or Indire (I) (Instr | Beneficial Ownership ct (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exerc | isable | Expiration Date | Title | or Numbe of | r | | | | |
| | (Fin MA BIOLO TE ROUTE Y NJ (St Security (Inst Stock, \$0.0 Stock, \$0.0 Stock, \$0.0 Stock, \$0.0 Stock, \$0.0 | (First) (MA BIOLOGICS, INC. TE ROUTE 17 Y NJ (State) (Table Security (Instr. 3) Stock, \$0.0001 par value per Stock, \$0.0001 par va | (First) (Middle) MA BIOLOGICS, INC. TE ROUTE 17 Y NJ 07446 (State) (Zip) Table I - N Security (Instr. 3) Stock, \$0.0001 par value per Table II 2. Conversion or Exercise Price of Derivative Security Stock Security (Month/Day/Year) (Month/Day/Year) | (First) | A A A A A A A A A A | ADMA ADMA ADMA ADMA ADMA ADMA ADMA BIOLOGICS, INC. TE ROUTE 17 A. If Amend ADMA ADM | ADMA BIC | ADMA BIOLO (First) (Middle) MA BIOLOGICS, INC. TE ROUTE 17 Table I - Non-Derivative Securities Acquired in Execution Date, if Month/Day/Year) Stock, \$0.0001 par value per 03/16/2015 Code (e.g., puts, calls, warrants in Code (instr. (instr. 3, 4) and 5) insposed of (instr. 8) insposed insp | ADMA BIOLOGICS (First) (Middle) 3. Date of Earliest Transaction 03/16/2015 Table I - Non-Derivative Securities Acquired (Month/Day/Year) 22A. Deemed Execution Date, if any (Month/Day/Year) 25tock, \$0.0001 par value per 25tock, \$0.0001 par value | ADMA BIOLOGICS, INC (First) (Middle) (| ADMA BIOLOGICS, INC. [ADM BIOLOGICS, INC.] ADMA BIOLOGICS, INC. [ADM BIOLOGICS, INC.] 3. Date of Earliest Transaction (Month/Day/Year) 03/16/2015 Table I - Non-Derivative Securities Acquired, Disposed of Code (Month/Day/Year) (Month/Day/Ye | ADMA BIOLOGICS, INC. ADMA ADMA BIOLOGICS, INC. ADMA BIOLOGICS, INC. | ADMA BIOLOGICS, INC. ADMA ADMA BIOLOGICS, INC. ADMA BIOLOGICS, INC. ADMA ADMA BIOLOGICS, INC. ADMA BIOLOGICS, | ADMA BIOLOGICS, INC. ADMA ABIOLOGICS, INC. ABIOLOGICS, INC | ADMA BIOLOGICS, INC. [ADMA] Clebeck all applies Code Name Code Code Nam | ADMA BIOLOGICS, INC. ADMA Cheek all applications Cheek all applications X Director X Director | ADMA BIOLOGICS, INC. ADMA ADMA BIOLOGICS, INC. ADMA BIOLOGI |

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$7.8399 to \$8.10 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 16, 2015.
- 2. 580,957 of these shares are held by Hariden, LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- 3. 35,700 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- 4. These shares are being purchased by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
- 5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$7.95 to \$7.9899 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 16, 2015.
- 6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$7.90 to \$8.01 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 17, 2015.
- 7. 41,200 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

/s/ Adam Grossman 03/18/2015

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.